China-U.S. Begin Meetings On Trade Issues Affecting Drug Makers
This article was originally published in PharmAsia News
Executive SummaryChinese and U.S. trade and foreign-relations officials begin two days of talks in Washington, D.C., expected to set the stage for resolving trade issues, many of which affect the pharmaceutical industry
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.